Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast CancerThomas Hatschek, Jonas Bergh, Hanna Fredholm et al.|JAMA Oncology|2021Cited by 58
Abstract P5-02-20: Correlative and longitudinal transcriptomic profiling predicts patient outcomes and the efficacy of neoadjuvant HER2-targeted treatments in the randomized PREDIX HER2 trialKang Wang, Theodoros Foukakis, Yajing Zhu et al.|Cancer Research|2023Cited by 0